Apellis Pharmaceuticals said Thursday that submission of additional clinical data to the Food and Drug Administration will delay the review of its experimental treatment for geographic atrophy — a chronic eye disease and a leading cause of blindness in older people.
The FDA was set to announce an approval decision for the Apellis drug on Nov. 26. The review will now be extended by three months to February 2023.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
